TDE-PH-308 (FREEDOM 308)

  • Research type

    Research Study

  • Full title

    TDE-PH-308: A 16-Week, International, Multicentre, Double-Blind, Randomised, Placebo-Controlled Study of the Efficacy and Safety of Oral UT-15C Sustained Release Tablets in Subjects with Pulmonary Arterial Hypertension

  • IRAS ID

    26468

  • Contact name

    Andrew J Peacock

  • Eudract number

    2009-009366-13

  • ISRCTN Number

    Not applicable

  • Clinicaltrials.gov Identifier

    NCT00887978

  • Research summary

    TDE-PH-308 - Is a 16-Week, international, multicentre, double-blind, randomised, placebo-controlled study of the efficacy and safety of oral UT-15C sustained release tablets in subjects with pulmonary arterial hypertension (PAH). PAH, which is defined as an elevation in pulmonary arterial pressure and pulmonary vascular resistance, is a severe hemodynamic abnormality common to a variety of diseases and syndromes. Elevation in pulmonary arterial pressure causes an increase in right ventricular afterload, impairing right ventricular function and ultimately leading to inactivity, right ventricular failure and death. Treprostinil Diethanolamine (UT-15C SR), an investigational drug, has been extensively characterised in well established models all confirming the suitability of the drug in the treatment of PAH following either the subcutaneous, intravenous, inhaled (all as treprostinil sodium) or oral (as treprostinil diethanolamine) routes of administration. This investigational drug is a tablet that is to be taken orally and its treatment effect is released over an extended period of time (sustained release, or SR). Approximately 300 participants will be included in this study from the Israel, Australia, Europe, USA and Canada. Participation in this study is voluntary and will last approximately 16 weeks from the start until the end of the study. The study is placebo controlled, meaning that one group of participants (approximately 50%) will receive UT-15C SR, whilst the other group (approximately 50%) will receive tablets that appear the same but do not contain active drug.

  • REC name

    West of Scotland REC 1

  • REC reference

    09/S0703/93

  • Date of REC Opinion

    13 Aug 2009

  • REC opinion

    Favourable Opinion